Earnings Analysis November 5, 2026

Precigen ($PGEN) Q3 2026 Earnings Analysis: Revenue Beats Estimates, First Quarterly Net Profit Turnaround

Earnings Report

Revenue: $74.15 million (vs. $2.92 million YoY, +2,437%, expected $71.56 million) ✅ Beat

EPS (Earnings Per Share): $0.08 (diluted, Q3 2026), decision pending due to thin analyst coverage

Guidance: Not provided · Achieved positive cash flow one quarter ahead of the previous 'by year-end' outlook

Stock Reaction: Regular session (pre-announcement session) -20.77% ($4.005, as of 11-06 04:17 KST)

Highlights

Revenue Growth: Papfjiemos revenue increased by 37% from the previous quarter to $72.90 million

Turnaround to Profitability: Q3 net income attributable to common stock was $35.80 million, turning from a $325.34 million loss a year ago

Cash Flow: Net cash inflow from operating activities was $11.90 million, achieved one quarter ahead of guidance

In its first year of commercialization, the company achieved both quarterly net profit and positive cash flow. The structure where expanded prescriptions lead to revenue has stabilized, and SG&A and R&D expenses have also decreased compared to a year ago.

Lowlights

Single-Product Dependency: All $72.96 million of Q3 product revenue came from Papfjiemos

Cash Balance: Cash, cash equivalents, and investments stood at $51.00 million at the end of September, down from $103.69 million at the beginning of the year

Interest Burden: Quarterly interest expense was $3.00 million, with long-term debt at $94.26 million

With only one axis of growth, the entire performance is vulnerable if the prescription trend falters. Accounts receivable increased to $96.49 million, which is a point that requires monitoring regarding the speed of collection.

What the Company Said

The company explained that Papfjiemos has established itself as the first-line standard of care for adult recurrent respiratory papillomatosis, with more than 500 patients having started treatment. They emphasized achieving positive cash flow one quarter ahead of the year-end target previously provided.

Market Reaction and Future Outlook

Based on regular trading session data prior to the earnings release, the stock price fell 20.77% to record $4.005. The company did not provide guidance for the next quarter, and it was also revealed that the earnings structure is heavily dependent on a single product.

It is necessary to confirm whether Q4 Prafgeomeos revenue continues its 37% quarter-over-quarter growth trend.

The progress of re-administration clinical enrollment and pediatric indication development is a key point to monitor.

The next key points to watch are the European Medicines Agency (EMA) authorization review results and whether the company maintains positive cash flow in Q4.

Earnings Call Summary

Once the company script is released following the earnings call, the key takeaways from the call will be added here. We will select and summarize only the most important details, such as how management explained the results and outlook, and what questions analysts asked.